Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

This trial tests whether olvimulogene nanivacirepvec (a modified oncolytic virus that stimulates the immune system) combined with chemotherapy and an immune checkpoint inhibitor works better than docetaxel (standard chemotherapy) as a second-line treatment for advanced non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic NSCLC (Stage III or IV) - You have already received at least 2 cycles (up to 6 cycles) of platinum-based chemotherapy combined with immunotherapy as initial treatment - Your cancer has since progressed while on or after that initial treatment - You have at least one measurable tumor outside the brain - You are in good general health (ECOG 0–1) **You may NOT be eligible if...** - You have an active urinary tract infection, pneumonia, or systemic infection - You have active or uncontrolled brain metastases - You have significant unresolved side effects (Grade ≥3) from prior cancer treatment - You require high-dose steroids or other immune suppression for managing prior treatment side effects Talk to your doctor to see if this trial is right for you.